Kidney Diseases

Nephrology
15
Pipeline Programs
9
Companies
50
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
5
7
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

Astellas
LEXISCANApproved
regadenoson
Astellas
Adenosine Receptor Agonist [EPC]intravenous2008
U
REGADENOSONApproved
regadenoson
Unknown Company
Adenosine Receptor Agonist [EPC]intravenous2022
Sanofi
RENVELAApproved
sevelamer carbonate
Sanofi
oral2009
U
SEVELAMER CARBONATEApproved
sevelamer carbonate
Unknown Company
oral2017

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
3 programs
1
1
1
Anti-thymocyte globulinPhase 45 trials
Sevelamer carbonatePhase 31 trial
SirolimusPhase 11 trial
Active Trials
NCT00305396Completed80Est. Mar 2005
NCT00268957Completed217Est. May 2007
NCT07412470Not Yet Recruiting526Est. Aug 2033
+4 more trials
Astellas
AstellasChina - Shenyang
2 programs
1
1
RegadenosonPhase 41 trial
everolimus and tacrolimusPhase 21 trial
Active Trials
NCT00325325Unknown40Est. Jun 2007
NCT00863707Completed511Est. Dec 2009
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Anti-thymocyte globulinPhase 41 trial
Active Trials
NCT01046955Completed38Est. Dec 2008
Novartis
NovartisBASEL, Switzerland
4 programs
2
Enteric-coated mycophenolate sodiumPhase 35 trials
zigakibartPhase 31 trial
Mycophenolate Mofetil (MMF): A Long-Term Data EvaluationN/A1 trial
prednisoneN/A
Active Trials
NCT00203671Completed651Est. May 2007
NCT02084446Completed120Est. Jul 2017
NCT00413920Completed222
+4 more trials
MediBeacon
MediBeaconGermany - Mannheim
2 programs
2
MB-102Phase 31 trial
MB-102 DMIDPhase 31 trial
Active Trials
NCT05777174Completed149Est. Apr 2024
NCT05943977Completed121Est. Nov 2023
DiaMedica Therapeutics
DiaMedica TherapeuticsMINNEAPOLIS, MN
1 program
1
DM199Phase 21 trial
Active Trials
NCT04123613CompletedEst. Mar 2022
Genomics
GenomicsUK - Oxford
1 program
Blood tests, TRACN/A1 trial
Active Trials
NCT07393594Not Yet Recruiting1,000Est. Oct 2028
ExThera Medical
ExThera MedicalCA - Martinez
1 program
Extracorporal therapyN/A1 trial
Active Trials
NCT04984902Unknown40Est. Apr 2023
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Kidney Health CoachingN/A1 trial
Active Trials
NCT06693661Not Yet RecruitingEst. Mar 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisEnteric-coated mycophenolate sodium
AstellasRegadenoson
SanofiAnti-thymocyte globulin
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
RocheAnti-thymocyte globulin
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium
NovartisEnteric-coated mycophenolate sodium

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 7,234 patients across 50 trials

NCT02084446NovartisEnteric-coated mycophenolate sodium

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Start: Dec 2012Est. completion: Jul 2017120 patients
Phase 4Completed
NCT00863707AstellasRegadenoson

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Start: Apr 2009Est. completion: Dec 2009511 patients
Phase 4Completed
NCT00564538SanofiAnti-thymocyte globulin

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

Start: Dec 2007Est. completion: Dec 2009100 patients
Phase 4Unknown
NCT00529269NovartisEnteric-coated mycophenolate sodium

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Start: Dec 2006200 patients
Phase 4Completed
NCT00400400NovartisEnteric-coated mycophenolate sodium

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Start: Oct 2006400 patients
Phase 4Completed
NCT00400647NovartisEnteric-coated mycophenolate sodium

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Start: Jul 2006Est. completion: Sep 2008136 patients
Phase 4Completed
NCT01046955RocheAnti-thymocyte globulin

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

Start: Nov 2005Est. completion: Dec 200838 patients
Phase 4Completed
NCT00229138NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

Start: Sep 2005Est. completion: Mar 2007291 patients
Phase 4Completed
NCT00239005NovartisEnteric-coated mycophenolate sodium

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Start: Sep 2005134 patients
Phase 4Completed
NCT00154310NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Start: Jun 2005Est. completion: Sep 2008300 patients
Phase 4Completed
NCT00149968NovartisEnteric-coated mycophenolate sodium

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Start: Apr 2005Est. completion: Jan 2007196 patients
Phase 4Completed
NCT00238953NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Start: Feb 2005Est. completion: Jun 200630 patients
Phase 4Completed
NCT00239083NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Start: Jan 2005Est. completion: Aug 200640 patients
Phase 4Completed
NCT00150020NovartisEnteric-coated mycophenolate sodium

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Start: Oct 2004728 patients
Phase 4Completed
NCT00149942NovartisEnteric-coated mycophenolate sodium

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Start: Oct 2004Est. completion: Aug 200623 patients
Phase 4Completed
NCT00154206NovartisEnteric-coated mycophenolate sodium

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Start: Sep 200415 patients
Phase 4Completed
NCT00154232NovartisEnteric-coated mycophenolate sodium

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Start: Jun 200446 patients
Phase 4Completed
NCT00150007NovartisEnteric-coated mycophenolate sodium

Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)

Start: Jun 2004335 patients
Phase 4Completed
NCT00305396SanofiSirolimus

Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation

Start: Apr 2004Est. completion: Mar 200580 patients
Phase 4Completed
NCT00240955NovartisEnteric-coated mycophenolate sodium

Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Start: Mar 2004Est. completion: May 200679 patients
Phase 4Completed
NCT00312143NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Start: Feb 2004Est. completion: Oct 200535 patients
Phase 4Completed
NCT00443937NovartisEnteric-coated mycophenolate sodium

Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients

Start: Jan 2004Est. completion: Mar 200615 patients
Phase 4Completed
NCT00154245NovartisEnteric-coated mycophenolate sodium

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Start: Jan 2004Est. completion: Mar 200620 patients
Phase 4Completed
NCT00239018NovartisEnteric-coated mycophenolate sodium

Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients

Start: Apr 2003Est. completion: Jul 2005144 patients
Phase 4Completed
NCT00238979NovartisEnteric-coated mycophenolate sodium

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Start: Jan 200350 patients
Phase 4Completed
NCT00238966NovartisEnteric-coated mycophenolate sodium

Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil

Start: Nov 2002Est. completion: Apr 2005187 patients
Phase 4Completed
NCT00241059NovartisEnteric-coated mycophenolate sodium

Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Start: Aug 2002Est. completion: Jan 2005183 patients
Phase 4Completed
NCT00574743NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

Start: Jan 2002162 patients
Phase 4Completed
NCT06858319Novartiszigakibart

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Start: Jul 2025Est. completion: Jun 2031220 patients
Phase 3Recruiting
NCT05777174MediBeaconMB-102

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Start: Mar 2023Est. completion: Apr 2024149 patients
Phase 3Completed
NCT05943977MediBeaconMB-102 DMID

A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants

Start: Mar 2023Est. completion: Nov 2023121 patients
Phase 3Completed
NCT01217723SanofiAnti-thymocyte globulin

Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation

Start: Apr 2010Est. completion: Jan 2014198 patients
Phase 3Unknown
NCT00413920NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

Start: Apr 2007222 patients
Phase 3Completed
NCT00405652NovartisEnteric-coated mycophenolate sodium

Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients

Start: Jan 2007Est. completion: Sep 200834 patients
Phase 3Completed
NCT00425308NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Start: Oct 200630 patients
Phase 3Completed
NCT00351377NovartisEnteric-coated mycophenolate sodium

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Start: Jun 2006Est. completion: Jun 2009111 patients
Phase 3Completed
NCT00369278NovartisEnteric-coated mycophenolate sodium

Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients

Start: Jun 2006Est. completion: Dec 2008128 patients
Phase 3Completed
NCT00268957SanofiSevelamer carbonate

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Start: Jan 2006Est. completion: May 2007217 patients
Phase 3Completed
NCT00284934NovartisEnteric-coated mycophenolate sodium

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

Start: Dec 2005Est. completion: Jun 200894 patients
Phase 3Completed
NCT00267150NovartisEnteric-coated mycophenolate sodium

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Start: Nov 2005Est. completion: Jan 200831 patients
Phase 3Completed
NCT00149903NovartisEnteric-coated mycophenolate sodium

Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients

Start: Jan 2005300 patients
Phase 3Completed
NCT00284921NovartisEnteric-coated mycophenolate sodium

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

Start: Apr 200460 patients
Phase 3Terminated
NCT00171379NovartisEnteric-coated mycophenolate sodium

Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant

Start: Mar 2004Est. completion: Jun 2005162 patients
Phase 3Completed
NCT00171392NovartisEnteric-coated mycophenolate sodium

Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus

Start: Mar 2004Est. completion: Jun 2005132 patients
Phase 3Completed
NCT00238446NovartisEnteric-coated mycophenolate sodium

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Start: Apr 2003
Phase 3Completed
NCT00239070NovartisEnteric-coated mycophenolate sodium

Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Start: Apr 2003Est. completion: May 200669 patients
Phase 3Completed
NCT00238940NovartisEnteric-coated mycophenolate sodium

Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants

Start: Feb 2003Est. completion: Sep 200555 patients
Phase 3Completed
NCT00238992NovartisEnteric-coated mycophenolate sodium

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Start: Dec 2002144 patients
Phase 3Completed
NCT00239044NovartisEnteric-coated mycophenolate sodium

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Start: Dec 200240 patients
Phase 3Completed
NCT00308425NovartisEnteric-coated mycophenolate sodium

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

Start: Oct 2002Est. completion: Jun 2005119 patients
Phase 3Completed

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 7,234 patients
9 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Transplant Rejection(16)Acute Kidney Injury(16)